Nature Communications · 2015 · 138 citations · 38 references
PharmacyBiotechnologyMolecular BiologyAntibody EngineeringMonoclonal AntibodiesProtein EngineeringAntibody Expression SystemsAntibody Fragment EngineeringImmunoglobulin FunctionProtein Expression EngineeringRecombinant Antibody ExpressionRecombinant Antibody ProductionAntibodiesAntibody Glycosylation ControlBacterial Antibody ExpressionDisulfide ChemistryDisulfide EngineeringEscherichia ColiEscherichia Coli Expression SystemsFc Receptors
Current methods for producing immunoglobulin G (IgG) antibodies in engineered cells often require refolding steps or secretion across one or more biological membranes. Here, we describe a robust expression platform for biosynthesis of full-length IgG antibodies in the Escherichia coli cytoplasm. Synthetic heavy and light chains, both lacking canonical export signals, are expressed in specially engineered E. coli strains that permit formation of stable disulfide bonds within the cytoplasm. IgGs with clinically relevant antigen- and effector-binding activities are readily produced in the E. coli cytoplasm by grafting antigen-specific variable heavy and light domains into a cytoplasmically stable framework and remodelling the fragment crystallizable domain with amino-acid substitutions that promote binding to Fcγ receptors. The resulting cytoplasmic IgGs—named 'cyclonals'—effectively bypass the potentially rate-limiting steps of membrane translocation and glycosylation.
38
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Paul Carter, Leonard G. Presta, C Gorman et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations
John F. Kearney, Andreas Radbruch, B Liesegang et al. · The Journal of Immunology · 1979 · 1.9K citations · Full text